Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck's quarterly results beat expectations, driven by strong sales of its immunotherapy Keytruda, which has been a top performer for the company. The newer injectable form of Keytruda, which was launched recently, contributed to the better-than-expected sales. This is significant as it provides patients with more treatment options and helps Merck maintain its competitive edge in the immunotherapy market.

The increased profit outlook is also a positive sign for Merck, indicating that the company expects its momentum to continue. Keytruda has been a key growth driver for Merck, and its success has helped the company offset losses from patent expirations of other drugs. The injectable form of Keytruda is likely to attract more patients and healthcare providers, given its convenience and potential for improved patient outcomes.

What's next to watch is how Merck's competitors respond to the growing demand for immunotherapies and the increasing popularity of injectable treatments. The pharmaceutical industry is highly competitive, and Merck's rivals are likely to focus on developing their own immunotherapies and innovative delivery methods. Additionally, investors will be monitoring Merck's progress in expanding Keytruda's label to treat new types of cancer and its efforts to develop new growth drivers to replace Keytruda's sales when its patent expires.

Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.